Study comparing firsekibart to anakinra for adult-onset Still's disease
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy clinical trials.
This trial tests a new drug called firsekibart against an existing drug, anakinra, for people with active adult-onset Still's disease. It aims to see if firsekibart is more effective in controlling symptoms like fever, joint pain, and rash.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with adult-onset Still's disease based on specific criteria, including high fever, joint pain, and typical rash.
- Your disease is active, meaning you have fever or a high C-reactive protein level (CRP >10 mg/L).
- If you take steroids (like prednisone), your dose has been stable for at least 1 week and does not exceed 1 mg per kg of body weight per day.
- You have not used certain medications (like JAK inhibitors, anakinra, or some immunosuppressants) within a specific time before the trial starts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares taking Firsekibart (a medicine that helps prevent gout attacks) on a fixed schedule versus only when you feel an attack coming on. It is for people who have already been on Firsekibart for 24 weeks without any flares, to see if continuing on a regular schedule is better than taking it "as needed."
This trial tests a new drug called picankibart to see if it helps people with active psoriatic arthritis who haven't gotten enough relief from standard treatments like NSAIDs or non-biologic DMARDs. It may be an option if you have at least 3 tender and 3 swollen joints and active or past plaque psoriasis.
This trial tests a new medication called Firsekibart for people with systemic sclerosis (scleroderma). The goal is to see if it helps reduce skin thickening and other symptoms, and it might be an option if standard treatments haven't worked well.
This study tests two new biologic medicines (goflikicept and olokizumab) as a second treatment option for people with adult-onset Still's disease. These drugs target inflammation to help control symptoms like fever, rash, and joint pain.
This trial tests whether adding a new medication (firsekibart) to the standard treatment for Kawasaki disease (immunoglobulin) works better than standard treatment alone. It aims to reduce the risk of heart problems and improve recovery.
This trial tests a new medicine called Firsekibart for people who have frequent gout attacks. It aims to see if the medicine can reduce the chance of another attack over 24 weeks.
Hear when a new Still's Disease, Adult-Onset trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.